To reduce cardiovascular complications in patients with type-2 diabetes, trials have shown that drug treatment for arterial hypertension is warranted for blood pressure over 140/80 mm Hg.
In a clinical trial involving 4733 type-2 diabetes patients with a high cardiovascular risk, the patients were divided into an "intensive" group (aiming for a systolic blood pressure of < 120 mm Hg) and a "standard" group (aiming for < 140 mm Hg).
The intensive treatment had no impact either on the total mortality rate, the cardiovascular mortality rate, the incidence of non-fatal coronary disease, or that of cardiac failure. One stroke was averted per approximately 700 patients treated over 5 years.
Hyperkalaemia (excess potassium) and orthostatic hypotension occurred more frequently in patients under intensive treatment.
In short, the results of this trial showed that reducing systolic blood pressure to < 120 mm Hg rather than to < 140 mm Hg did not reduce mortality in type-2 diabetics with a high cardiovascular risk.
The modest reduction in the number of strokes was achieved at the cost of more frequent adverse effects.
©Prescrire 1 March 2011
"Type 2 diabetes: targeting blood pressure below 140/80 mmHg" Prescrire Int 2011; 20 (114): 77. (Pdf, subscribers only).